Who is sponsoring NCT03961126?

NCT03961126 is sponsored by Instituto de Investigacion Sanitaria La Fe.

What condition does NCT03961126 study?

NCT03961126 studies Vulvar Lichen Sclerosus.

Is NCT03961126 still recruiting?

NCT03961126 is currently completed. Last updated 11 June 2020.

Last reviewed 2020-06-11 · How we verify

NCT03961126

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Vulvar Lichen Sclerosus Treatment Using Adipose Tissue Associated With Autologous Platelet-rich Plasma.

Completed Phase 2 Last updated 11 June 2020

What this trial tests

Phase 2 trial testing Injection of autologous fatty tissue associated with autologous platelet-rich plasma. in Vulvar Lichen Sclerosus in 20 participants. Completed in 12 December 2019.

Timeline

6 September 2017

Primary endpoint
12 December 2019

12 December 2019

Quick facts

Lead sponsor	Instituto de Investigacion Sanitaria La Fe
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	6 September 2017
Primary completion	12 December 2019
Estimated completion	12 December 2019
Sites	1 location across Spain

Drugs / interventions tested

Injection of autologous fatty tissue associated with autologous platelet-rich plasma. — full drug profile →
Corticosteroids (clobetasol 0.05%) — full drug profile →

Conditions studied

Vulvar Lichen Sclerosus — all drugs for Vulvar Lichen Sclerosus →

Sponsor

Instituto de Investigacion Sanitaria La Fe — full company profile →

Who can join

Adults 18 to 70, female only, with Vulvar Lichen Sclerosus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

LIQUENIA clinical trial is a phase II, controlled, prospective and unicentric study to assess vulvar lichen sclerosus (VLS) treatment using adipose tissue associated with autologous platelet-rich plasma (PRP) coming from the inner side of the patients' thighs, which aims to restore the structure and elasticity of the affected vulvar subunits, and to improve vulvar subunits lesions and symptoms, therefore, patients' quality of life from the early phases of the treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Lichen sclerosus: The 2023 update.
De Luca DA, Papara C, Vorobyev A, Staiger H, et al · · 2023 · cited 94× · PMID 36873861 · DOI 10.3389/fmed.2023.1106318

Verify or expand the search:

Other recruiting trials for Vulvar Lichen Sclerosus

Currently open trials in the same condition.

NCT06662942 — StrataMGT in the Reduction of Vulvar Lichen Sclerosus (LS) Symptoms · Phase 1 · recruiting
NCT06661382 — Use of Platelet Rich Plasma from Cord Blood Vs Placebo in the Treatment of Vulvar Lichen Sclerosus · Phase 1, PHASE2 · recruiting
NCT04967170 — A Study to Evaluate Platelet Rich Plasma to Treat Vulvar Lichen Sclerosus · Phase 1, PHASE2 · active not recruiting

Other Instituto de Investigacion Sanitaria La Fe trials

Trials by the same sponsor.

NCT07402083 — Administration of Extracellular Vesicles From Donor Human Milk in Preterm Infants · recruiting
NCT07238608 — Impact of UFPs and MNPs on Fetal Health · recruiting
NCT06950996 — A Clinical Evaluation of AI Solutions Developed in the CHAIMELEON Project for Cancer: Prostate, Lung, Breast, Colon and · completed
NCT06866769 — Efficacy of Biomarkers and CEUS Versus CTA in AAA Follow-up Post-EVAR · recruiting
NCT07478445 — Home Rehabilitation After Hip Fracture · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03961126 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto de Investigacion Sanitaria La Fe
Last refreshed: 11 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03961126.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing